申请人:Kissei Pharmaceutical Co., Ltd.
公开号:US04226878A1
公开(公告)日:1980-10-07
Novel imidazole derivatives of the general formula (I): ##STR1## wherein Y is a carboxyl group, an alkoxycarbonyl group, a cyano group, a hydroxymethyl group, an aminomethyl group, a formyl group or a carbamoyl group, and A and B, which may be the same or different, each is a straight- or branched-chain alkylene or alkenylene group, and n and m, which may be the same or different, each is zero or 1, with the proviso that when A is methylene group or n is zero, m is 1; and pharmaceutically acceptable salts thereof. These compounds have a strong inhibitory effect on thromboxane synthetase from rabbit platelet microsomes, and are useful as therapeutically active agents for the treatment of inflammation, hypertension, thrombus, cerebral apoplexy and asthma.
新型咪唑衍生物的一般化学式(I)如下:其中Y是羧基、烷氧羰基、氰基、羟甲基、氨甲基、甲酰基或氨基甲酰基,A和B可以相同也可以不同,每个都是直链或支链烷基或烯基基团,n和m可以相同也可以不同,每个都是零或1,但当A是亚甲基基团或n为零时,m为1;以及其药学上可接受的盐。这些化合物对于兔血小板微粒体中的前列腺素合成酶具有强烈的抑制作用,并可用作治疗活性剂,用于治疗炎症、高血压、血栓、脑卒中和哮喘。